Acuta Capital Partners LLC Has $15.47 Million Stake in Vaxcyte, Inc. (NASDAQ:PCVX)

Acuta Capital Partners LLC increased its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 22.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 135,400 shares of the company's stock after acquiring an additional 25,000 shares during the period. Vaxcyte comprises approximately 12.5% of Acuta Capital Partners LLC's portfolio, making the stock its biggest holding. Acuta Capital Partners LLC owned about 0.11% of Vaxcyte worth $15,472,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of PCVX. Riverview Trust Co bought a new position in Vaxcyte during the third quarter worth about $27,000. Fifth Third Bancorp purchased a new stake in shares of Vaxcyte during the second quarter worth $35,000. Blue Trust Inc. boosted its holdings in shares of Vaxcyte by 33.5% in the third quarter. Blue Trust Inc. now owns 371 shares of the company's stock worth $42,000 after acquiring an additional 93 shares during the period. J.Safra Asset Management Corp grew its position in shares of Vaxcyte by 649.4% in the second quarter. J.Safra Asset Management Corp now owns 607 shares of the company's stock valued at $46,000 after purchasing an additional 526 shares in the last quarter. Finally, Quest Partners LLC bought a new stake in shares of Vaxcyte during the 2nd quarter valued at $70,000. 96.78% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have weighed in on PCVX. Mizuho lifted their target price on Vaxcyte from $113.00 to $163.00 and gave the company an "outperform" rating in a report on Tuesday, September 10th. Bank of America raised their price target on shares of Vaxcyte from $101.00 to $140.00 and gave the company a "buy" rating in a report on Wednesday, September 4th. Needham & Company LLC reaffirmed a "buy" rating and issued a $140.00 price target on shares of Vaxcyte in a report on Wednesday, November 6th. Jefferies Financial Group boosted their target price on Vaxcyte from $108.00 to $129.00 and gave the stock a "buy" rating in a research report on Tuesday, September 3rd. Finally, BTIG Research raised their price target on Vaxcyte from $98.00 to $160.00 and gave the company a "buy" rating in a report on Tuesday, September 3rd. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $147.50.

Vaxcyte Trading Up 2.8 %

Shares of PCVX stock traded up $2.53 during trading hours on Thursday, hitting $93.98. 785,268 shares of the company's stock were exchanged, compared to its average volume of 907,004. The company has a market capitalization of $11.71 billion, a PE ratio of -20.43 and a beta of 1.01. Vaxcyte, Inc. has a 12-month low of $48.81 and a 12-month high of $121.06. The business's 50 day simple moving average is $106.48 and its 200-day simple moving average is $89.97.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its earnings results on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, topping analysts' consensus estimates of ($1.10) by $0.27. During the same quarter in the previous year, the firm posted ($0.91) earnings per share. Equities analysts anticipate that Vaxcyte, Inc. will post -4.14 EPS for the current year.

Insider Transactions at Vaxcyte

In other news, COO Jim Wassil sold 10,000 shares of the company's stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $111.93, for a total transaction of $1,119,300.00. Following the completion of the transaction, the chief operating officer now directly owns 207,503 shares of the company's stock, valued at approximately $23,225,810.79. This represents a 4.60 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Elvia Cowan sold 5,000 shares of the stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $107.67, for a total transaction of $538,350.00. Following the sale, the senior vice president now owns 12,723 shares of the company's stock, valued at approximately $1,369,885.41. This represents a 28.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 102,464 shares of company stock worth $11,455,576. Company insiders own 3.10% of the company's stock.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.